In addition, in vivo animal models can be used to test lactate-reducing strategies—particularly MCT1 inhibitors (e.g., AZD3965)—for their effects on erythrocyte function and tumor oxygenation, thereby strengthening the biological validity of the hypothesis. The gene discussed is SLC16A1; the disease is neoplasm.